Andrea Patricelli Malizia
Andrea P. Malizia, Ph.D., MBA, is a board member and chief executive officer at Iama Therapeutics, a company whose mission is to develop innovative medicines for brain disorders with unmet medical needs. Before joining Iama Therapeutics, Andrea was the director of strategy and operations at IMT School for Advanced Studies Lucca. In collaboration with Intesa Sanpaolo Innovation Center, he led a multidisciplinary team to assess neuroscientific and behavioral variables in the decision-making process in organizations. He co-founded two strategy consulting firms, Koeus Srl, a spin-off of IMT Lucca (Italy), and QStat Consulting in the greater Boston area, focused on designing corporate and management strategies applied to competitive markets in the life science sector. Earlier in his career, he launched and served as scientific founder at BeRNA Therapeutics LLC, whose mission was to develop and deliver drugs to cure chronic pain transcutaneously. In that capacity, he was the architect, lead, and implementer of the entrepreneurial initiatives, supported by an international Scientific Advisory Board, to secure the intellectual property necessary to succeed. Prior he was a team leader and scientist in biologics drug discovery for neurodegenerative diseases at Biogen, where he was responsible for identifying new potential therapeutic targets and supporting R2D transition. Prior to joining Biogen in 2013, he was the recipient of an NIH-T32 Ruth L. Kirschstein Institutional National Research Service Award to investigate the impact of oxidative stress and tRNA fragments in mitochondrial diseases as a postdoctoral fellow at Children’s Hospital Boston and research fellow in pediatrics at Harvard Medical School, Harvard University. During his Ph.D. fellowship at the University College Dublin, he received several university seed funds and young scientist awards from the European Respiratory Society to investigate the translational opportunities in targeting molecular mechanisms of pulmonary fibrosis.
Andrea believes that business leaders in the pharmaceutical and biotechnology industries have the obligations to ensure that patients and individuals have access to high-quality, safe, effective, and affordable therapies; while taking a public stand on public policy matters as a core part of their responsibility to shareholders, industry, and society. He has co-authored many manuscripts and chapter books in cognitive psychology in organizations, behavioral strategy, and translational medicine.
He holds a B.S. from the University of Siena (Italy), a Ph.D. in translational medicine from the University College Dublin (Ireland), and an MBA from Northeastern University (MA, USA).